Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Alisporivir and EDP-239 Co-administration in Healthy Subjects
NCT02173574Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EDP-239 in hepatitis C (HCV), sponsored by Enanta Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration-time Curve at Day 3, Adverse Events and 3 more. Started Aug 2014; status: completed.
02
Drugs
EDP-239
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02173574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173574.